Author:
Patel Prashant,J Shah Shrenik,Choudhary Arpan
Abstract
Background Management of high risk prostate cancer (HRPC) is in evolving stage. Effectiveness of the various treatment strategies is being explored. We examined the short term efficacy of laparoscopic radical prostatectomy (LRP) in treatment of patients with HRPC.
Methods Retrospective observational study had 140 HRPC patients of Indian origin, based on D’Amico classification system. Baseline workup was completed. Perioperative parameters and pathological findings were recorded. Multivariate analysis was performed to find predictive factors of pathological stage and PSM. 5 year biochemical recurrence free survival (BCRFS), cancer specific survival (CSS) and overall survival (OS) were calculated.
Results Mean age and PSA were 67.24±7.37 years and 23.29 ng/ml respectively. Three fourth of patients had a biopsy GS ≥8. 53.6% of patients were of clinical stage (CS) ≤T2; while 46.4% were of stage ≥T3. Conversion to open surgery rate was 15%. Mean operative time was 210 minutes; blood loss 230 ml; hospital stay 3 days; catheterization time 14 days; grade II or more complication rate 22.1%; LN positivity 20.0%; PSM rate 25.7%; upstaging 35.7%; down-staging 14.3%; pT2 31.4%; pT3a 26.4%; pT3b 42.2%. GS and CS were predictive of pathological stage and PSM respectively. 89.3% of cases were continent postoperatively. 5 year BCRFS, CSS and OS were 68.3%, 89.2% and 78.7% respectively.
Conclusions LRP is feasible and effective initial treatment for HRPC. Perioperative morbidity is acceptable. Accurate staging helps in better planning of the adjuvant therapy. Good short term survival can be achieved with multimodal therapy.
Publisher
Asian Medical Press Limited
Reference21 articles.
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4): 225-49.
2. Zeigler-Johnson CM, Rennert H, Mittal RD, Jalloh M, Sachdeva R, Malkowicz SB, Mandhani A, Mittal B, Gueye SM, Rebbeck TR: Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol 2008, 15(3): 4056-64.
3. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML: Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008, 179(4): 1354-60; discussion 1360-1.
4. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR: Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 2005, 173(5): 1557-1561.
5. Furukawa J, Miyake H, Inoue TA, Ogawa T, Tanaka H, Fujisawa M: Oncologic Outcome of Radical Prostatectomy as Monotherapy for Men with High-risk Prostate Cancer. Curr Urol 2016, 9(2): 67-72.